AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Core Viewpoint - A class action lawsuit has been filed against Agenus Inc. for alleged violations of federal securities laws, claiming that the company made materially false and misleading statements regarding its business and clinical prospects [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Agenus securities between January 23, 2023, and July 17, 2024 [2]. - Allegations include that the combination therapy of botensilimab and balstilimab was less effective than represented, leading to overstated clinical results and regulatory prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Agenus have until November 5, 2024, to request to be appointed as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. - Bronstein, Gewirtz & Grossman, LLC has a history of recovering hundreds of millions of dollars for investors in securities fraud cases [6].